GH Secretagogues
Ipamorelin
← Back to Library
Limited / unverified FDA safety flag Limited / unverified GH Axis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 2, 5, 10 mg
Dosing window: Pre-Bed Fasted
Receptor / target: GHS-R1a
Properties: GH Secretagogue
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg - 200mcg once daily | Administered pre-bed, usually stacked with CJC-1295. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Saturation Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 300mcg 2x to 3x daily | Ipamorelin has a saturation dose of roughly 300mcg/injection. Dosing higher yields diminishing returns. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: Gradual Approach
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mcg 1x Daily at bedtime fasted | |
| Weeks 3-4 | 150 mcg 1x Daily at bedtime fasted | |
| Weeks 5-8 | 200 mcg 1x Daily at bedtime fasted | |
| Weeks 9-12 | 250 mcg 1x Daily at bedtime fasted |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHS-R1a); route Subcutaneous; timing Pre-Bed Fasted. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.
Independent evidence
Independent safety notes: FDA lists ipamorelin acetate in category 2/withdrawn lists with immunogenicity/impurity concerns and serious adverse events reported in IV literature.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer or history of malignancy: GH/IGF-1 elevation may promote tumor cell proliferation. Limited / unverified
- History of hormone-sensitive malignancies (breast, prostate, colorectal): IGF-1 is a growth factor for these tumor types. Limited / unverified
- Active acromegaly or pituitary disorders involving GH excess. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Diabetes mellitus or significant insulin resistance: GH elevation reduces insulin sensitivity; monitor fasting glucose. Limited / unverified
- Concurrent use with GHRP-2 or GHRP-6: receptor competition at GHS-R1a; do not combine two GHRPs. Limited / unverified
- Concurrent use with HGH 191aa: additive GH elevation creates redundant axis overstimulation. Limited / unverified
- Concomitant glucocorticoid therapy: suppresses pituitary GH response. Limited / unverified
- Pregnancy: safety not established. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity to ipamorelin or any formulation excipients. Limited / unverified
- Pediatric use in children with closed growth plates. Limited / unverified
- Severe cardiac disease or heart failure: GH elevation can increase cardiac workload. Limited / unverified
Side effects (limited evidence)
- Headache: most commonly reported adverse effect; caused by acute GH pulse-induced vasodilation; typically occurs in the first 1-2 weeks and diminishes with continued use; reported in approximately 20-35% of users in early weeks. Limited / unverified
- Mild fatigue or lethargy: transient; within 30-60 minutes post-injection; associated with the GH pulse. Limited / unverified
- Dizziness or lightheadedness: approximately 10-15% anecdotally; transient vasodilation; resolves within 30 minutes. Limited / unverified
- Injection site irritation: redness, swelling, minor discomfort; reported in approximately 20-30% with subcutaneous injection. Limited / unverified
- Mild water retention: GH-mediated sodium and fluid retention; approximately 15% anecdotally; less than CJC-1295 alone; more common in first 2-4 weeks. Limited / unverified
- Mild nausea: rare; less than 5% at standard doses; more common at 300mcg+. Limited / unverified
- Slight increase in appetite: modest orexigenic effect from GHS-R1a activation; minimal compared to GHRP-6. Limited / unverified
- Joint stiffness: GH-mediated periarticular fluid; typically at higher-dose multi-injection protocols. Limited / unverified
- Tingling or numbness in hands or feet: paresthesia; less common than with CJC-1295 DAC. Limited / unverified
- Vivid dreams: GH elevation during nocturnal sleep cycle. Limited / unverified
- Transient mild hypoglycemia: possible when combining with CJC-1295 in a fasted state; GH pulse transiently shifts glucose partitioning. Limited / unverified
- Long-term insulin resistance (theoretical, dose and duration dependent): sustained IGF-1 elevation may reduce insulin sensitivity over extended cycles; no direct evidence from ipamorelin-specific studies. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: